JUL 25, 2017 5:45 AM PDT

FDA Approves First Sickle Cell Drug in 2 Decades

WRITTEN BY: Xuan Pham

For the first time in almost two decades, patients with sickle cell disease will have access to a new drug thanks to a recent FDA approval.

Image credit: Wikipedia.org

The drug is known as Endari (L-glutamine oral powder), and it is approved for patients five years or older with sickle cell disease.

"Endari is the first treatment approved for patients with sickle cell disease in almost 20 years," said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncology Center of Excellence. "Until now, only one other drug was approved for patients living with this serious, debilitating condition."

Sickle cell disease is a group of blood disorders characterized by abnormalities in the red blood cells. Under healthy circumstances, red blood cells resemble filled-in donuts that contain hemoglobin, a protein that carries oxygen. In sickle cell disease, the hemoglobin is defective, which causes the red blood cells to distort into a crescent, sickle shape. This malformed version is stiff and prone to clumping along the walls of blood vessels.

When sickled red blood cells block blood flow, tissues and organs become deprived of oxygen, which can cause major organ damage over time. Another complication of sickle cell disease is pulmonary hypertension - a high blood pressure condition caused by the blockages of the vessels in the lungs. Finally, sickled red blood cells don’t last very long in the body, and their premature breakdown contributes to anemia, a condition marked by low number of red blood cells. Sickle cell anemia is the most common type of sickle cell disease.

The FDA based its approval on randomized clinical trials that compared Endari to placebo in a group of patients with the disease. Over the course of 48 weeks, the research team showed that patients treated with Endari had less hospital visits for pain, and fewer days in the hospital. Endari-treated patients also had fewer instances of acute chest syndrome, a serious complication of sickle cell disease, as compared to placebo-treated patients.

With the approval, Endari could soon be accessible to the 100,000 Americans diagnosed with the disease. Of note, the inherited disease is more common in minority groups, such as Latinos and African Americans, in whom the disease affects 1 in every 13 people.

Although Endari showed compelling results in the clinical trial, it should not be mistaken for a cure. The drug was approved based on its capacity to "reduce severe complications associated with the blood disorder.” The drug also brings its own side effects, which include constipation, nausea, headache, cough, and chest pain. Nevertheless, Endari’s approval marks a great milestone for the hundreds of thousands of people living with sickle cell disease.

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 11, 2020
Neuroscience
JAN 11, 2020
Molecular Therapy to Self-Repair Nerve Cells
Neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's, and Huntington's Disease are predicated ...
JAN 30, 2020
Genetics & Genomics
JAN 30, 2020
How To Choose The Right DNA Testing Kit For You
One of the most exciting scientific advancements in the past decade, at least in terms of its impact on pop culture, was ...
MAR 29, 2020
Cancer
MAR 29, 2020
MicroRNA as a New Way to Test for Lung Cancer
The most common, and most deadly, cancer across the world is lung cancer. If caught early, lung cancer has quite a low m ...
APR 01, 2020
Cardiology
APR 01, 2020
Avoiding Caries in Children
Thankfully, children are free of many of the chronic diseases that plague older populations. That said, one of the most ...
APR 13, 2020
Cancer
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
APR 29, 2020
Clinical & Molecular DX
APR 29, 2020
Move and Detect : Diagnosis of Neonatal Sepsis Using Fluorescent Micromotors
According to the World Health Organization (WHO), sepsis occurs when the body’s response to an infection injures i ...
Loading Comments...